Abstract
Background Pulmonary gas exchange is assessed by the transfer factor of the lungs (TL) for carbon monoxide (TLCO), and can also be measured with inhaled xenon-129 (129Xe) MRI. A model has been proposed to estimate TL from 129Xe MRI metrics, but this approach has not been fully validated and does not utilise the spatial information provided by 3D 129Xe MRI.
Methods Three models for predicting TL from 129Xe MRI metrics were compared; (1) a previously-published physiology-based model, (2) multivariable linear regression and (3) random forest regression. Models were trained on data from 150 patients with asthma and/or chronic obstructive pulmonary disease. The random forest model was applied voxel-wise to 129Xe images to yield regional TL maps.
Results Coefficients of the physiological model were found to differ from previously reported values. All models had good prediction accuracy with small mean absolute error (MAE); (1) 1.24±0.15 mmol·min−1·kPa−1, (2) 1.01±0.06 mmol·min−1·kPa−1, (3) 0.995±0.129 mmol·min−1·kPa−1. The random forest model performed well when applied to a validation group of post-COVID-19 patients and healthy volunteers (MAE=0.840 mmol·min−1·kPa−1), suggesting good generalisability. The feasibility of producing regional maps of predicted TL was demonstrated and the whole-lung sum of the TL maps agreed with measured TLCO (MAE=1.18 mmol·min−1·kPa−1).
Conclusion The best prediction of TLCO from 129Xe MRI metrics was with a random forest regression framework. Applying this model on a voxel-wise level to create parametric TL maps provides a useful tool for regional visualisation and clinical interpretation of 129Xe gas exchange MRI.
Footnotes
This manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.
Conflicts of interest: J.H.P-M has no conflicts of interest to declare. L.J.S. is a co-investigator on investigator-lead research grants from The Cystic Fibrosis Trust, Vertex Pharmaceuticals and The Sheffield Children's Hospital Charity, and has received support from AstraZeneca to attend research meetings. H.M. is a co-investigator on investigator-lead research grants from GlaxoSmithKline and the EPSRC and has received support from AstraZeneca to attend research meetings. B.A.T has no conflicts of interest to declare. G.J.C has no conflicts of interest to declare. N.J.S. has no conflicts of interest to declare. J.M.W has received investigator led grants from AstraZeneca, GlaxoSmithKline, Vertex and GE Healthcare, has received consulting fees from GE Healthcare and consultancy fees from Vertex Ltd for speaking at image advisory meetings for lung MRI and received support from AstraZeneca to attend the 2021 European Respiratory Society meeting.
This is a PDF-only article. Please click on the PDF link above to read it.
- Received May 11, 2024.
- Accepted August 15, 2024.
- Copyright ©The authors 2024
This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions{at}ersnet.org